- Conditions
- Pancreatic Cancer Metastatic, Pancreatic Adenocarcinoma Metastatic
- Interventions
- Botensilimab, Balstilimab, Chloroquine Phosphate, Celecoxib, Nab paclitaxel, Gemcitabine, Cisplatin
- Drug
- Lead sponsor
- HonorHealth Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 312
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes
- Interventions
- rivogenlecleucel, rimiducid, Cyclophosphamide, haplo-HSCT
- Biological · Drug · Procedure
- Lead sponsor
- Bellicum Pharmaceuticals
- Industry
- Eligibility
- 12 Years to 70 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 2
- States / cities
- Nashville, Tennessee • San Antonio, Texas
- Conditions
- Hematologic Malignancy
- Interventions
- Abatacept
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Eosinophilic Esophagitis Caused by Food (Disorder)
- Interventions
- Assay directed diet change
- Diagnostic Test
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 0 Years to 90 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2029
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- AML, MDS
- Interventions
- SOC + TSC-101, Control, SOC + TSC-100
- Drug · Other
- Lead sponsor
- TScan Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 310 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 21
- States / cities
- Duarte, California • Aurora, Colorado • Denver, Colorado + 16 more
- Conditions
- Relapsed/Refractory B-cell Non-Hodgkin Lymphoma, Lymphomas Non-Hodgkin&Amp;Amp;#39;s B-Cell
- Interventions
- GLPG5101
- Genetic
- Lead sponsor
- Lakefront Biotherapeutics NV
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Anaplastic Large-Cell Lymphoma, Non-Hodgkin Lymphoma, T-Cell Lymphoma
- Interventions
- brentuximab vedotin, doxorubicin, prednisone, vincristine, cyclophosphamide
- Drug
- Lead sponsor
- Seagen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 452 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 32
- States / cities
- Gilbert, Arizona • Duarte, California • Stanford, California + 24 more
- Conditions
- Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
- Interventions
- Nivolumab, Pembrolizumab
- Biological
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2037
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Prostate Cancer, Recurrent Prostate Carcinoma, Stage IV Prostate Adenocarcinoma
- Interventions
- Ipilimumab, Nivolumab, Enzalutamide
- Biological · Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
- Interventions
- Axicabtagene Ciloleucel, Biospecimen Collection, Chemotherapy, Fecal Microbiota Transplantation, Leukapheresis, Placebo Administration
- Biological · Procedure · Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nonmalignant Neoplasm
- Interventions
- biologic sample preservation procedure, cytology specimen collection procedure
- Other
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 15,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2040
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma, Large B-cell Lymphoma, B-cell Non-Hodgkin Lymphoma
- Interventions
- Surovatamig, Prednisone (or equivalent), Rituximab, Cyclophosphamide, Vincristine, Doxorubicin, Acalabrutinib
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 408 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 12
- States / cities
- Boston, Massachusetts • Hackensack, New Jersey • New Brunswick, New Jersey + 8 more
- Conditions
- Kidney Transplant Failure and Rejection
- Interventions
- Tacrolimus (TAC), Sirolimus, Alemtuzumab, Mycophenolate mofetil (MMF)
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Acute Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Acute Lymphoblastic Leukemia, Mixed Lineage Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma, Juvenile Myelomonocytic Leukemia
- Interventions
- CliniMACS Cell Processing System for TCRαβ + T Cell and CD45RA Depleted Peripheral Stem Cell Addback
- Device
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- Up to 25 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Relapsed/Refractory Follicular Lymphoma
- Interventions
- Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine, Lenalidomide, Rituximab, Doxorubicin, Vincristine, Prednisone, Bendamustine
- Biological · Drug
- Lead sponsor
- Kite, A Gilead Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 231 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 12
- States / cities
- Duarte, California • Stanford, California • Tampa, Florida + 8 more
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Psychosocial Effects of Cancer and Its Treatment
- Interventions
- psychosocial assessment and care
- Procedure
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2017
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Pediatric Heart Transplantation, Pediatric Heart Transplant Recipients
- Interventions
- Induction Therapy, Tacrolimus, Mycophenolate Mofetil, Intraoperative plasma exchange/pheresis, Short-term post-operative plasmapheresis, Immunoglobulins, Intravenous, Prednisone
- Drug · Procedure
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Up to 21 Years
- Enrollment
- 290 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 7
- States / cities
- Boston, Massachusetts • St Louis, Missouri • New York, New York + 4 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- APLA12, Placebo
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- HPV-Related Cervical Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
- Interventions
- Two IM injections Lenti-HPV-07, One IM injection Lenti-HPV-07
- Drug
- Lead sponsor
- Theravectys S.A.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 4
- States / cities
- Orlando, Florida • Tampa, Florida • Tulsa, Oklahoma
- Conditions
- Positron-Emission Tomography, Immunomodulation, Metastatic Solid Malignancies, Hodgkin Lymphoma
- Interventions
- ⁸⁹Zr-Df-IAB22M2C Infusion
- Drug
- Lead sponsor
- ImaginAb, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • New York, New York • Philadelphia, Pennsylvania
- Conditions
- Metastatic Melanoma, Mucosal Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Uveal Melanoma AJCC v7, Unresectable Melanoma
- Interventions
- Bevacizumab, Ipilimumab, Laboratory Biomarker Analysis, Nab-paclitaxel, Pharmacological Study
- Biological · Other · Drug
- Lead sponsor
- Academic and Community Cancer Research United
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 13
- States / cities
- San Francisco, California • Jacksonville, Florida • Chicago, Illinois + 10 more
- Conditions
- Respiratory Tract Viral Infections, Human Metapneumovirus (hMPV) Infection, Parainfluenza (PIV) Infection, Respiratory Syncytial Viral (RSV) Infection, Influenza Infection
- Interventions
- ALVR106, Placebo
- Biological
- Lead sponsor
- AlloVir
- Industry
- Eligibility
- 17 Years to 75 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 21
- States / cities
- Scottsdale, Arizona • Duarte, California • Gainesville, Florida + 16 more
- Conditions
- Glioblastoma
- Interventions
- B-cell vaccination
- Biological
- Lead sponsor
- Catalina Lee Chang
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Autoimmune Diseases, Ulcerative Colitis, Multiple Sclerosis, Scleroderma, Ankylosing Spondylitis, Celiac Disease, Non-radiographic Axial Spondyloarthritis (Nr-axSpA), Crohn&Amp;#39;s Disease, Birdshot Chorioretinitis
- Interventions
- Companion blood samples with procedure
- Procedure
- Lead sponsor
- TScan Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 238 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 11
- States / cities
- Orange, California • Sherman Oaks, California • Skokie, Illinois + 7 more